News

Oncoinvent ASA (OSE: ONCIN) a clinical stage radiopharmaceutical company developing innovative treatments for solid cancers, invites for a presentation of the top-line results from the Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases originating from colorectal cancer.

Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent’s novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer

Oslo, 14 May 2025: The annual general meeting of Oncoinvent ASA was held today, on 14 May 2025, as a digital meeting through Microsoft Teams. All proposals on the agenda were adopted in accordance with the board of directors’ proposals and the proposals from the nomination committee.

The minutes of the annual general meeting are attached hereto and are also available on the company’s website www.oncoinvent.com/investors/general-meetings.

Oncoinvent ASA has today published the annual report for 2024. The annual report is attached and is also available on the Company’s website, www.oncoinvent.com.

In connection with the release of the first quarter 2025 company update, Oncoinvent invites for a
Live streamed of quarterly presentation in English on Wednesday 30th of April at 11.00 AM CEST. A webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar.

Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The trial was closed for recruitment at the end of 2023 and patients are currently in long-term follow-up.

Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced that the safety data from the patients in the safety lead-in cohort of its ongoing Phase 2 trial evaluating Radspherin® for the treatment of peritoneal carcinomatosis from ovarian cancer has been reviewed by the company and study investigators. No safety concerns were identified, and based on this review, the company is pleased to confirm that the randomised part of the trial is now initiated, with the first patient successfully enrolled.

Primary insider Anne Cecile Alvik, Head of QA and Board member (employee representative) of Oncoinvent ASA, has 5. March 2025 acquired 8 500 shares in Oncoinvent ASA at an average price of NOK 1,694 per share. Following this transaction, Anne Cecilie owns 13 200 shares in Oncoinvent ASA.

Oncoinvent ASA (OSE: ONCIN) a clinical stage 2 radiopharmaceutical company developing novel radiopharmaceutical therapies against cancer, announces its fourth quarter 2024 results today

Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the successful enrollment of the sixth patient into the safety lead-in cohort of its ongoing Phase 2 trial evaluating Radspherin® for the treatment of peritoneal carcinomatosis from ovarian cancer.

In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events:

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will be presenting the company and participate in the following conferences:

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 6 February 2025 regarding the final result of the subsequent offering in the Company, where a total of 5,500,000 new shares were subscribed and allocated at a subscription price of NOK 2 per share.

Reference is made to the stock exchange announcement by Oncoinvent ASA
(“Oncoinvent” or the “Company”) on 22 January 2025 regarding the launch of a
subsequent offering of up to 5,500,000 new shares (“Offer Shares”) in the
Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 2
per Offer Share (the “Subsequent Offering”), as well as the stock exchange
announcement from earlier today, regarding today being the last day of the
subscription period in the Subsequent Offering.

Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 22 January 2025 regarding the launch of a subsequent offering of up to 5,500,000 new shares (“Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 2 per Offer Share (the “Subsequent Offering”).

Oncoinvent ASA (“Oncoinvent” or the “Company”) has today granted 3,560,000 share options under its long term share incentive scheme for employees (the “Option Program”), each with a strike price of NOK 2.4991 of these 2,210,000 share options were granted to primary insiders of the Company. For more information about the grant of share options to primary insiders, see the attached forms.
Following today’s grant, a total of 4,789,808 share options have been granted under the Option Program.

Oncoinvent ASA (“Oncoinvent” or the “Company”) is pleased to announce that it has today successfully completed the bookbuilding process for a private placement of new shares and that gross proceeds of NOK 130 million is being raised by the issuance of 65,000,000 new shares (the “Offer Shares”) at a subscription price of NOK 2 per share (the “Private Placement”).

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has entered into an agreement with ARTBIO, a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies. As part of the agreement, ARTBIO will rent space and equipment, acquire access to some of Oncoinvent’s radioprotection expertise and analytical services, and purchase select R&D equipment. The agreement between Oncoinvent and ARTBIO shows a joint commitment to maximizing resource utilization and operational efficiency in a field which is constrained by a limited supply of these specialized facilities worldwide.

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the treatment of peritoneal carcinomatoses. The studies were closed for recruitment at the end of 2023, and patients are currently in long-term follow-up. The readout confirmed the previously published results on efficacy and adds further confidence in the ongoing randomized controlled Phase 2 clinical trial for Radspherin® in patients with ovarian cancer.

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the publication of data from the Phase 1/2a study of Radspherin® in colorectal cancer patients in the peer-reviewed Journal of Surgical Oncology. The results, previously presented at the 2023 Peritoneal Surface Oncology Group International (PSOGI) Congress in Venice last year, show encouraging 18 months safety and efficacy data from the 23 patients enrolled in the Phase 1 part of the RAD-18-002 study in colorectal cancer patients.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual panel discussion at the JonesTrading Virtual Radiopharma Day on Tuesday, October 29, 2024 at 2:35 p.m. ET.

U.S. Food and Drug Administration (FDA) recently granted Fast Track designation for Radspherin® for the treatment of patients with peritoneal metastases from ovarian cancer

New CEO brings over 15 years of proven leadership experience, including deep expertise growing international radiopharmaceutical companies.

Oncoinvent ASA, a clinical stage radiopharmaceutical company advancing alpha emitter therapy across a variety of peritoneal metastases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Radspherin® for the treatment of patients with peritoneal metastases from ovarian cancer.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit on Monday, May 20, 2024 at 9:00 a.m. ET.

Newly elected members of Board of Directors consist of internationally merited business and clinical leaders

Formation of Scientific and Clinical Advisory Board leverages expertise of renowned Oncoinvent founders to support pipeline advancement

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.

Progressing to study Radspherin® in the first-line treatment setting for ovarian cancer

IND clearance is now obtained for both lead indications for Radspherin®

This marks the first IND clearance for initiation of Radspherin® clinical trials in the US

At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences

Robust safety profile demonstrated, no serious adverse events related to Radspherin® reported
Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)

Recommended dose of 7 MBq established following completion of dose escalation; no dose-limiting toxicity observed

Presentation on September 30, 2023

Anders brings nearly 30 years of international and diverse experience in oncology-focused drug development and commercialization.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.

Median PFS (progression free survival) was not reached at 15 months, and no patients at recommended dose of 7 MBq had peritoneal recurrences

All dose levels of Radspherin®, including recommended dose of 7 MBq, were well tolerated at 15 months with no serious adverse events related to Radspherin® reported

Radspherin® is currently being evaluated in two ongoing Phase 1/2A trials for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer

Poster discussion session on June 5, 2023 at 1:15 p.m. ET

Publications highlight the safety and tolerability of Radspherin® for patients and those externally exposed to radiation, all dose levels were well tolerated with dose level toxicity (DLT) not reached.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced strong progress with clinical trials, including patient recruitment and efficacy signals.  Further updates will be provided in an upcoming investor conference call.

First patient has been treated in the RAD-18-002 phase 2A clinical study

All dose levels of Radspherin® were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study.

Radspherin® is currently being evaluated in two ongoing Phase 1 trials for the treatment of peritoneal carcinomatosis from ovarian cancer and colorectal cancer

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming virtual investor conferences:

Twenty-three colorectal cancer patients in total have been enrolled in the Radspherin® RAD-18-002 phase 1 clinical trial and treated with Radspherin®. No SAE’s related to the Radspherin® treatment have been observed.

Oncoinvent presents preclinical dosimetry data documenting a therapeutic relevant biodistribution of Radspherin® as well as preclinical data on the potential synergistic effects of Radspherin® with existing cancer therapies. The company also will present preclinical results of a novel 212Pb product candidate

The company makes three important new appointments to the clinical and regulatory teams in preparation for the upcoming Radspherin® phase 2 clinical trials

Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-001 study to fourth and final cohort dose level cohort

Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin®

Norwegian radiopharmaceutical company is contemplating a private placement to raise funds for the phase 2A development of it’s lead product candidate Radspherin®

7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study

Safety Monitoring Committee review of second dose-level cohort allows advancement of Phase 1 RAD-18-001 study to third cohort dose level cohort

Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-002 study to fourth and final cohort dose level cohort

Safety Monitoring Committee review of first dose-level cohort allows progression of RAD-18-001 study to second dose level cohort

Reference is made to the extraordinary general meeting notice published on 20th of May 2020 regarding a repair issue with gross proceeds of up to NOK 9 million directed towards eligible shareholders and company employees (the “Repair Issue”). The Repair Issue consisted of an offer of minimum 1 and maximum 175,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible shareholders and an offer of minimum 1 and maximum 25,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible employees. The subscription period for the Repair Issue ended on 29th of May 2020 at 16.30 hours (CEST). The subscription price in the Repair Issue was NOK 45 per Offer Share.